Could a common arthritis drug ease rare genetic skin disease?
NCT ID NCT02113904
First seen Apr 23, 2026 · Last updated Apr 29, 2026 · Updated 2 times
Summary
This study tested the drug Humira (adalimumab) in 11 people with Netherton syndrome, a rare genetic skin condition that causes severe redness, itching, and pain. The goal was to see if Humira could reduce skin inflammation and improve quality of life after 3 months of treatment, with a 3-month follow-up. While not a cure, the hope was to provide meaningful symptom relief for this chronic, incurable disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NETHERTON SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Necker Enfants Malades hospital
Paris, Paris, 75015, France
Conditions
Explore the condition pages connected to this study.